Hematopoietic Biorepository and Cellular Therapy

Case Western Reserve University, Cleveland OH

Investigators

Linked publications & trials

Abstract

HEMATOPOIETIC BIOREPOSITORY AND CELLULAR THERAPY SHARED RESOURCE PROJECT SUMMARY/ABSTRACT The Hematopoietic Biorepository and Cellular Therapy Shared Resource (HBCT SR) is an essential asset to Case Comprehensive Cancer Center (Case CCC) members' research, illustrated by the breadth of scientific program involvement and reflected in the large number of investigators who use this SR. Importantly, the HBCT SR has played a pivotal role in both the clinical translation and manufacturing support for multiple cell therapy products for cancer related first in human clinical trials. The mission of the SR is to provide resources and services related to the procurement, processing, production, storage, banking, analysis and distribution of cells derived from human blood, bone marrow, and umbilical cords. The SR also operates a Clinical Cellular Therapy facility that supports clinical-grade cell manufacturing for investigational and standard of care therapy. The Specific Aims of the HBCT SR are to: 1. Support the development and implementation of cellular therapy clinical trials. Support is provided in all aspects of clinical cell therapy, from technology transfer of investigator projects to clinically applicable manufacturing and compliance IND enabling validations and IND content, to GMP compliant manufacture and distribution of clinical grade cell products. 2. Enable access to annotated clinical blood and bone marrow samples to support basic and translational research. An active IRB is maintained to consent and procure blood and bone marrow samples and related case and tissue data from cancer patients and healthy donors for distribution to Case CCC investigators. 3. Assist users with specialized hematopoietic cell-based assays. Support is provided to perform a variety of CFU assays to assess hematopoietic progenitor cells as well as to isolate hematopoietic cell subsets such as CD34+ cells from blood and bone marrow samples. In the current funding cycle, the HBCT SR has provided services and products to 86 investigators, of whom 52% are Case CCC members, accounting for 73% of total usage, from all 6 Case CCC research programs. Through maintaining a biorepository of annotated blood and bone marrow samples for use in research, assisting investigators with specialized hematopoietic and supporting clinical cellular therapy activities from the preclinical phase through clinical trial implementation, the HBCT SR plays a major role in enabling basic, translational and clinical research at the Case CCC.